{"id":"ogt918","safety":{"commonSideEffects":[{"effect":"Fall","drugRate":"37.8%","placeboRate":"","totalAtRisk":172,"totalAffected":65,"trialsReporting":3},{"effect":"Headache","drugRate":"28.9%","placeboRate":"","totalAtRisk":166,"totalAffected":48,"trialsReporting":2},{"effect":"COVID-19","drugRate":"50.6%","placeboRate":"","totalAtRisk":87,"totalAffected":44,"trialsReporting":2},{"effect":"Arthralgia","drugRate":"23.5%","placeboRate":"","totalAtRisk":166,"totalAffected":39,"trialsReporting":2},{"effect":"Nasopharyngitis","drugRate":"22.9%","placeboRate":"","totalAtRisk":166,"totalAffected":38,"trialsReporting":2},{"effect":"Myalgia","drugRate":"19.3%","placeboRate":"","totalAtRisk":166,"totalAffected":32,"trialsReporting":2},{"effect":"DIARRHOEA","drugRate":"73.8%","placeboRate":"","totalAtRisk":42,"totalAffected":31,"trialsReporting":1},{"effect":"Back pain","drugRate":"17.4%","placeboRate":"","totalAtRisk":172,"totalAffected":30,"trialsReporting":3},{"effect":"Pain in extremity","drugRate":"16.9%","placeboRate":"","totalAtRisk":166,"totalAffected":28,"trialsReporting":2},{"effect":"Diarrhea","drugRate":"31.0%","placeboRate":"","totalAtRisk":87,"totalAffected":27,"trialsReporting":2},{"effect":"Nausea","drugRate":"15.1%","placeboRate":"","totalAtRisk":166,"totalAffected":25,"trialsReporting":2},{"effect":"Musculoskeletal pain","drugRate":"15.1%","placeboRate":"","totalAtRisk":166,"totalAffected":25,"trialsReporting":2},{"effect":"Fatigue","drugRate":"13.5%","placeboRate":"","totalAtRisk":178,"totalAffected":24,"trialsReporting":4},{"effect":"Urinary tract infection","drugRate":"14.5%","placeboRate":"","totalAtRisk":166,"totalAffected":24,"trialsReporting":2},{"effect":"Oropharyngeal pain","drugRate":"13.3%","placeboRate":"","totalAtRisk":166,"totalAffected":22,"trialsReporting":2},{"effect":"FLATULENCE","drugRate":"50.0%","placeboRate":"","totalAtRisk":42,"totalAffected":21,"trialsReporting":1},{"effect":"Upper respiratory tract infection","drugRate":"9.9%","placeboRate":"","totalAtRisk":172,"totalAffected":17,"trialsReporting":3},{"effect":"Cough","drugRate":"19.5%","placeboRate":"","totalAtRisk":87,"totalAffected":17,"trialsReporting":2},{"effect":"Muscle spasms","drugRate":"9.6%","placeboRate":"","totalAtRisk":166,"totalAffected":16,"trialsReporting":2},{"effect":"Pyrexia","drugRate":"9.0%","placeboRate":"","totalAtRisk":166,"totalAffected":15,"trialsReporting":2},{"effect":"Vaccination complication","drugRate":"18.5%","placeboRate":"","totalAtRisk":81,"totalAffected":15,"trialsReporting":1},{"effect":"TREMOR","drugRate":"35.7%","placeboRate":"","totalAtRisk":42,"totalAffected":15,"trialsReporting":1},{"effect":"Contusion","drugRate":"8.4%","placeboRate":"","totalAtRisk":166,"totalAffected":14,"trialsReporting":2},{"effect":"Dizziness","drugRate":"8.4%","placeboRate":"","totalAtRisk":166,"totalAffected":14,"trialsReporting":2},{"effect":"Sinusitis","drugRate":"7.8%","placeboRate":"","totalAtRisk":166,"totalAffected":13,"trialsReporting":2},{"effect":"Hypertension","drugRate":"7.2%","placeboRate":"","totalAtRisk":166,"totalAffected":12,"trialsReporting":2},{"effect":"Diarrhoea","drugRate":"12.9%","placeboRate":"","totalAtRisk":85,"totalAffected":11,"trialsReporting":1},{"effect":"Rash","drugRate":"6.6%","placeboRate":"","totalAtRisk":166,"totalAffected":11,"trialsReporting":2},{"effect":"Rhinitis","drugRate":"6.4%","placeboRate":"","totalAtRisk":172,"totalAffected":11,"trialsReporting":3},{"effect":"Pain","drugRate":"6.0%","placeboRate":"","totalAtRisk":166,"totalAffected":10,"trialsReporting":2},{"effect":"Abdominal pain","drugRate":"5.8%","placeboRate":"","totalAtRisk":172,"totalAffected":10,"trialsReporting":3},{"effect":"Abdominal pain upper","drugRate":"5.8%","placeboRate":"","totalAtRisk":172,"totalAffected":10,"trialsReporting":3},{"effect":"Muscular weakness","drugRate":"5.8%","placeboRate":"","totalAtRisk":172,"totalAffected":10,"trialsReporting":3},{"effect":"Dyspnea","drugRate":"11.1%","placeboRate":"","totalAtRisk":81,"totalAffected":9,"trialsReporting":1},{"effect":"HEADACHE","drugRate":"21.4%","placeboRate":"","totalAtRisk":42,"totalAffected":9,"trialsReporting":1},{"effect":"PARAESTHESIA","drugRate":"21.4%","placeboRate":"","totalAtRisk":42,"totalAffected":9,"trialsReporting":1},{"effect":"Limb injury","drugRate":"4.8%","placeboRate":"","totalAtRisk":166,"totalAffected":8,"trialsReporting":2},{"effect":"Influenza","drugRate":"9.9%","placeboRate":"","totalAtRisk":81,"totalAffected":8,"trialsReporting":1},{"effect":"Neck pain","drugRate":"9.9%","placeboRate":"","totalAtRisk":81,"totalAffected":8,"trialsReporting":1},{"effect":"Depression","drugRate":"9.9%","placeboRate":"","totalAtRisk":81,"totalAffected":8,"trialsReporting":1},{"effect":"FATIGUE","drugRate":"19.0%","placeboRate":"","totalAtRisk":42,"totalAffected":8,"trialsReporting":1},{"effect":"Dyspnoea","drugRate":"7.7%","placeboRate":"","totalAtRisk":91,"totalAffected":7,"trialsReporting":2},{"effect":"Ear pain","drugRate":"8.0%","placeboRate":"","totalAtRisk":87,"totalAffected":7,"trialsReporting":2},{"effect":"Toothache","drugRate":"8.6%","placeboRate":"","totalAtRisk":81,"totalAffected":7,"trialsReporting":1},{"effect":"Vomiting","drugRate":"8.0%","placeboRate":"","totalAtRisk":87,"totalAffected":7,"trialsReporting":2},{"effect":"Ligament sprain","drugRate":"8.6%","placeboRate":"","totalAtRisk":81,"totalAffected":7,"trialsReporting":1},{"effect":"Tremor","drugRate":"8.0%","placeboRate":"","totalAtRisk":87,"totalAffected":7,"trialsReporting":2},{"effect":"DIZZINESS","drugRate":"16.7%","placeboRate":"","totalAtRisk":42,"totalAffected":7,"trialsReporting":1},{"effect":"Flatulence","drugRate":"6.6%","placeboRate":"","totalAtRisk":91,"totalAffected":6,"trialsReporting":2},{"effect":"Gastroesophageal reflux disease","drugRate":"7.4%","placeboRate":"","totalAtRisk":81,"totalAffected":6,"trialsReporting":1}]},"_chembl":null,"_dailymed":null,"_scrapedAt":"2026-03-28T05:22:05.860Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T10:14:12.457924+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT07399704","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease","status":"RECRUITING","sponsor":"Azafaros A.G.","startDate":"2026-02-04","conditions":"GM2 Gangliosidosis, Niemann-Pick Type C Disease","enrollment":21},{"nctId":"NCT06121011","phase":"","title":"A Global Prospective Observational Registry of Patients With Pompe Disease","status":"RECRUITING","sponsor":"Amicus Therapeutics","startDate":"2024-02-16","conditions":"Pompe Disease","enrollment":500},{"nctId":"NCT04138277","phase":"PHASE3","title":"A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)","status":"COMPLETED","sponsor":"Amicus Therapeutics","startDate":"2019-12-18","conditions":"Pompe Disease (Late-onset)","enrollment":119},{"nctId":"NCT04808505","phase":"PHASE3","title":"A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18","status":"RECRUITING","sponsor":"Amicus Therapeutics","startDate":"2023-07-18","conditions":"Glycogen Storage Disease Type II Infantile Onset","enrollment":36},{"nctId":"NCT02325362","phase":"PHASE2, PHASE3","title":"Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-03-17","conditions":"Cystic Fibrosis","enrollment":16},{"nctId":"NCT03911505","phase":"PHASE3","title":"ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amicus Therapeutics","startDate":"2020-02-13","conditions":"Pompe Disease (Late-onset)","enrollment":21},{"nctId":"NCT02675465","phase":"PHASE1, PHASE2","title":"First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221","status":"COMPLETED","sponsor":"Amicus Therapeutics","startDate":"2016-04","conditions":"Pompe Disease","enrollment":29},{"nctId":"NCT03822013","phase":"PHASE3","title":"Effects of Miglustat Therapy on Infantile Type of Sandhoff and Taysachs Diseases (EMTISTD)","status":"TERMINATED","sponsor":"Tehran University of Medical Sciences","startDate":"2019-01-14","conditions":"GM2 Gangliosidosis, Supportive Care","enrollment":30},{"nctId":"NCT03729362","phase":"PHASE3","title":"A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease","status":"COMPLETED","sponsor":"Amicus Therapeutics","startDate":"2018-12-04","conditions":"Pompe Disease (Late-onset)","enrollment":125},{"nctId":"NCT04327973","phase":"","title":"Expanded Access for ATB200/AT2221 for the Treatment of IOPD","status":"AVAILABLE","sponsor":"Amicus Therapeutics","startDate":"","conditions":"Pompe Disease Infantile-Onset","enrollment":""},{"nctId":"NCT05174039","phase":"PHASE1, PHASE2","title":"An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of Subjects With Batten Ceroid Lipofuscinosis, Neuronal 3 (CLN3) Disease","status":"COMPLETED","sponsor":"Beyond Batten Disease Foundation","startDate":"2022-03-10","conditions":"Batten Disease","enrollment":6},{"nctId":"NCT03910621","phase":"PHASE4","title":"Safety and Efficacy of Miglustat in Chinese NPC Patients","status":"COMPLETED","sponsor":"Actelion","startDate":"2020-04-02","conditions":"Niemann-Pick Disease, Type C","enrollment":17},{"nctId":"NCT00517153","phase":"PHASE2","title":"Miglustat in Niemann-Pick Type C Disease","status":"COMPLETED","sponsor":"Actelion","startDate":"2002-01","conditions":"Niemann-Pick Type C Disease","enrollment":29},{"nctId":"NCT00319046","phase":"PHASE3","title":"Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease","status":"COMPLETED","sponsor":"Actelion","startDate":"2006-02-01","conditions":"Gaucher Disease Type 1","enrollment":42},{"nctId":"NCT04768166","phase":"PHASE2","title":"Testing Miglustat Administration in Subjects With Spastic Paraplegia 11","status":"COMPLETED","sponsor":"IRCCS Fondazione Stella Maris","startDate":"2021-06-15","conditions":"Hereditary Spastic Paraparesis","enrollment":10},{"nctId":"NCT02030015","phase":"PHASE4","title":"Synergistic Enteral Regimen for Treatment of the Gangliosidoses","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2015-12-22","conditions":"GM1 Gangliosidoses, GM2 Gangliosidoses, Tay-Sachs Disease","enrollment":16},{"nctId":"NCT02520934","phase":"NA","title":"Miglustat on Gaucher Disease Type IIIB","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2015-07","conditions":"Gaucher Disease","enrollment":19},{"nctId":"NCT02185651","phase":"PHASE1","title":"A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction","status":"TERMINATED","sponsor":"University of Florida","startDate":"2016-10","conditions":"Pompe Disease, Hypersensitivity Reaction","enrollment":2},{"nctId":"NCT01451879","phase":"","title":"Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies","status":"COMPLETED","sponsor":"University of Florida","startDate":"2008-10","conditions":"Pompe Disease","enrollment":11},{"nctId":"NCT00316498","phase":"PHASE1","title":"Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2002-10-17","conditions":"Niemann Pick Diseases","enrollment":30},{"nctId":"NCT00041535","phase":"PHASE2","title":"OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2002-07-05","conditions":"Gaucher Disease","enrollment":30},{"nctId":"NCT00418847","phase":"PHASE2","title":"Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2004-07","conditions":"Gangliosidoses GM2","enrollment":5},{"nctId":"NCT01822028","phase":"PHASE1","title":"Two Period / Two Treatment Cross-over to Assess the Effect of Florastor® on Gastrointestinal Tolerability, Safety, and PK in Healthy Subjects Receiving Zavesca®","status":"COMPLETED","sponsor":"Actelion","startDate":"2013-03","conditions":"Diarrhea","enrollment":42},{"nctId":"NCT00742092","phase":"PHASE2","title":"Miglustat in Cystic Fibrosis","status":"COMPLETED","sponsor":"Actelion","startDate":"2008-08","conditions":"Cystic Fibrosis","enrollment":11},{"nctId":"NCT01760564","phase":"PHASE3","title":"Application of Miglustat in Patients With Niemann-Pick Type C","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2008-01","conditions":"Niemann-Pick Disease Type C","enrollment":5},{"nctId":"NCT00945347","phase":"PHASE2","title":"Does a Nasal Instillation of Miglustat Normalize the Nasal Potential Difference in Cystic Fibrosis Patients ?","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2009-07","conditions":"Cystic Fibrosis","enrollment":10},{"nctId":"NCT00537602","phase":"PHASE2","title":"Miglustat / OGT 918 in the Treatment of Cystic Fibrosis","status":"TERMINATED","sponsor":"Actelion","startDate":"2007-11","conditions":"Cystic Fibrosis","enrollment":6},{"nctId":"NCT00194649","phase":"PHASE4","title":"Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2005-06","conditions":"Contraception","enrollment":8},{"nctId":"NCT00672022","phase":"PHASE3","title":"Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses","status":"COMPLETED","sponsor":"Children's National Research Institute","startDate":"2004-07","conditions":"GM2 Gangliosidoses, Tay-Sachs, Sandhoff Disease","enrollment":10},{"nctId":"NCT00002079","phase":"PHASE2","title":"Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)","status":"COMPLETED","sponsor":"G D Searle","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00001993","phase":"PHASE2","title":"Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3","status":"COMPLETED","sponsor":"G D Searle","startDate":"","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT00000692","phase":"PHASE1","title":"Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex","status":"COMPLETED","sponsor":"G D Searle","startDate":"","conditions":"HIV Infections","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"OGT918","genericName":"OGT918","companyName":"National Eye Institute (NEI)","companyId":"national-eye-institute-nei","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":1,"trialStats":{"total":9,"withResults":4},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T10:14:12.457924+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}